Get notified when PCVX files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Red Flags Detected

  • The Notes Are a New Class of Securities For Which No Market Currently Exists. We Do Not Intend to Apply to List the Notes On Any Securities Exchange or For Quotation On Any Inter-dealer Quotation System. (new) — The notes will have no trading market, severely limiting liquidity for investors.
  • Before July 15, 2032, You May Convert Your Notes Only If Specific Conditions Are Met. (new) — Conversion restrictions until 2032 may prevent noteholders from realizing the value of the underlying common stock.
  • The Indenture For the Notes Will Not Contain Any of These Covenants or Restrictions or Otherwise Place Any Meaningful Restrictions On Our Ability to Operate Our Business As Management Deems Appropriate. (new) — Lack of protective covenants exposes noteholders to increased credit risk.
  • We Have Not Reached a Final Determination Regarding the Accounting Treatment For the Notes, and the Description Above Is Preliminary. (new) — Uncertainty in accounting treatment could lead to unexpected impacts on financial statements.
NASDAQ: PCVX Vaxcyte, Inc. 424B5

Vaxcyte launches convertible notes offering with terms to be determined, alongside concurrent equity raise

Filed October 6, 2026 · ~1 min read

Key Changes

  • high

    Vaxcyte is offering convertible senior notes due 2032, but the aggregate principal amount, interest rate, and conversion price are left blank in this preliminary prospectus supplement.

    The Offering verify on EDGAR →
  • high

    The company plans to use net proceeds from this offering and a concurrent equity offering to fund VAX-31 clinical development, manufacturing scale-up, commercial launch preparation, and general corporate purposes.

    Use of Proceeds verify on EDGAR →
  • high

    The notes will not be listed on any exchange, and there is currently no trading market, posing significant liquidity risk for noteholders.

    Risk Factors verify on EDGAR →

3 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (TLRY 10-Q) is open in full — no account needed.

Partner

Trade PCVX commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov

Figures/quotes linked to EDGAR · Narrative written by AI · Oct 6, 2026 · How we verify